… gefitinib than erlotinib (63.2% vs. 38.8%, p < 0.001) (Table 1). We stratified … patients
according to different lines of gefitinib or erlotinib. The disparities of choices on gefitinib or erlotinib …

… why their efficacy, especially in patients with EGFR-wt NSCLC, and … studies have yet compared
gefitinib and erlotinib for adverse … of differences in AEs and efficacy between gefitinib and …

… difference between gefitinib and erlotinib as salvage therapy for advanced NSCLC. The
median TTF of around 3.4–5.5 months was compatible with results of clinical trials in East Asia …

… rash and diarrhea in patients compared with gefitinib. Therefore, … no difference in PFS
between the erlotinib- and gefitinib-… matched Asian patients (121 pairs) with NSCLC (13). These …

… , gefitinib and erlotinib have not been directly compared in terms of efficacy and other clinical
outcomes in patients … outcomes between gefitinib‐treated and erlotinib‐treated patients with …

… compared gefitinib with erlotinib for the second-line treatment of advanced NSCLC, but it was
small in sample size (48 patients … with direct comparison of gefitinib with erlotinib that had …

… -free survival (PFS) in patients harboring an activating EGFR mutation. We compared the
clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had …

… , gefitinib, erlotinib and icotinib had similar effectiveness for the treatment of patients with …
meta-analysis was performed to compare the effectiveness and adverse effects of gefitinib, …

… However, whether gefitinib, erlotinib, or afatinib is most appropriate … compare the effectiveness
of gefitinib, erlotinib, and afatinib. We retrospectively reviewed the records of 310 patients …

… This study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a
better safety profile compared to erlotinib. Therefore, gefitinib could be considered a better …